However, despite these successes the majority of patients in many cancer types do not truly benefit from PD-L1/PD-1 blockade therapies and show resistance, either intrinsic resistance when the treatment directly fails, or acquired resistance where a proportion of responders will also develop resistance. Here, CD274 is linked to cancer.